EA003128B1 - Способ лечения рассеянного склероза и фармацевтический состав, содержащий сополимер-1 - Google Patents

Способ лечения рассеянного склероза и фармацевтический состав, содержащий сополимер-1 Download PDF

Info

Publication number
EA003128B1
EA003128B1 EA199900621A EA199900621A EA003128B1 EA 003128 B1 EA003128 B1 EA 003128B1 EA 199900621 A EA199900621 A EA 199900621A EA 199900621 A EA199900621 A EA 199900621A EA 003128 B1 EA003128 B1 EA 003128B1
Authority
EA
Eurasian Patent Office
Prior art keywords
copolymer
multiple sclerosis
pharmaceutical composition
cells
eae
Prior art date
Application number
EA199900621A
Other languages
English (en)
Russian (ru)
Other versions
EA199900621A1 (ru
Inventor
Рут Арнон
Адриан Гилберт
Милка Линенберг
Ривка Ривон-Крейтман
Михаэль Села
Двора Тейтельбаум
Original Assignee
Еда Ресёрч Энд Девелопмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Еда Ресёрч Энд Девелопмент Ко., Лтд. filed Critical Еда Ресёрч Энд Девелопмент Ко., Лтд.
Publication of EA199900621A1 publication Critical patent/EA199900621A1/ru
Publication of EA003128B1 publication Critical patent/EA003128B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
EA199900621A 1997-01-10 1998-01-12 Способ лечения рассеянного склероза и фармацевтический состав, содержащий сополимер-1 EA003128B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
PCT/US1998/000375 WO1998030227A1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Publications (2)

Publication Number Publication Date
EA199900621A1 EA199900621A1 (ru) 2000-02-28
EA003128B1 true EA003128B1 (ru) 2003-02-27

Family

ID=11069682

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900621A EA003128B1 (ru) 1997-01-10 1998-01-12 Способ лечения рассеянного склероза и фармацевтический состав, содержащий сополимер-1

Country Status (18)

Country Link
EP (1) EP0975351B1 (cg-RX-API-DMAC7.html)
JP (1) JP4216342B2 (cg-RX-API-DMAC7.html)
KR (1) KR20000070058A (cg-RX-API-DMAC7.html)
CN (1) CN100528222C (cg-RX-API-DMAC7.html)
AT (1) ATE356608T1 (cg-RX-API-DMAC7.html)
AU (1) AU737287B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI9807076B8 (cg-RX-API-DMAC7.html)
CA (1) CA2277365C (cg-RX-API-DMAC7.html)
CZ (1) CZ297983B6 (cg-RX-API-DMAC7.html)
DE (1) DE69837324T2 (cg-RX-API-DMAC7.html)
EA (1) EA003128B1 (cg-RX-API-DMAC7.html)
HU (1) HU226612B1 (cg-RX-API-DMAC7.html)
IL (2) IL119989A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ336690A (cg-RX-API-DMAC7.html)
PL (1) PL193300B1 (cg-RX-API-DMAC7.html)
SK (1) SK284029B6 (cg-RX-API-DMAC7.html)
WO (1) WO1998030227A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA98214B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521448A (ja) * 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
CA2375874A1 (en) * 1999-06-04 2000-12-14 Chris Polman Use of riluzole for the treatment of multiple sclerosis
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
CA2411536A1 (en) * 2000-06-05 2001-12-13 V. Wee Yong The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
EP1459065B1 (en) 2001-12-04 2010-07-28 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
JP2007521249A (ja) * 2003-01-24 2007-08-02 エラン ファーマシューティカルズ,インコーポレイテッド 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
HRP20160455T1 (hr) 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
RS55607B1 (sr) 2009-08-20 2017-06-30 Yeda Research & Development Company Ltd Niskofrekventna terapija glatiramer acetatom
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
WO2014058976A2 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN112649537B (zh) * 2015-04-28 2024-03-29 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
US10323289B2 (en) 2017-06-26 2019-06-18 Institut Pasteur Treatments to eliminate HIV reservoirs and reduce viral load

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
EP0975351A4 (en) 2002-05-15
EP0975351A1 (en) 2000-02-02
PL193300B1 (pl) 2007-01-31
PL334566A1 (en) 2000-03-13
BR9807076B1 (pt) 2013-10-29
WO1998030227A1 (en) 1998-07-16
HUP0001917A2 (hu) 2000-10-28
CN1249690A (zh) 2000-04-05
CA2277365C (en) 2011-04-12
EA199900621A1 (ru) 2000-02-28
IL119989A0 (en) 1997-04-15
CZ297983B6 (cs) 2007-05-16
ATE356608T1 (de) 2007-04-15
AU5819598A (en) 1998-08-03
SK93199A3 (en) 2000-11-07
JP4216342B2 (ja) 2009-01-28
EP0975351B1 (en) 2007-03-14
IL130820A (en) 2007-03-08
SK284029B6 (sk) 2004-08-03
KR20000070058A (ko) 2000-11-25
HUP0001917A3 (en) 2001-12-28
CA2277365A1 (en) 1998-07-16
HK1025737A1 (en) 2000-11-24
BR9807076A (pt) 2000-05-02
BRPI9807076B8 (pt) 2021-05-25
HU226612B1 (en) 2009-04-28
DE69837324T2 (de) 2007-11-29
DE69837324D1 (de) 2007-04-26
NZ336690A (en) 2001-05-25
CN100528222C (zh) 2009-08-19
AU737287B2 (en) 2001-08-16
ZA98214B (en) 1999-08-11
CZ243799A3 (cs) 2000-06-14
JP2001511121A (ja) 2001-08-07

Similar Documents

Publication Publication Date Title
US6214791B1 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
CA2277365C (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
WO1998030227A9 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
KR100239743B1 (ko) 인슐린을 함유하는 타입 1 당뇨병 치료용 경구투여, 장내투여 또는 흡입경구투여용 제제
JPH05508621A (ja) 自己抗原の経口投与による自己免疫疾患のダウンコントロール
CN102458476A (zh) 用于治疗多发性硬化症的组合物及方法
JP2005532380A (ja) アラニルアミノペプチダーゼの阻害剤の使用および該阻害剤を含む薬学的配合物
JP3183378B2 (ja) ムチン産生促進剤
Schwab et al. WIN 8077 IN TREATMENT OF MYASTHENIA GRAVIS: USE OF N, N′-BIS (2-DIETHYLAMINOETHYL) OXAMIDE BIS-2-CHLOROBENZYL CHLORIDE IN FIFTY PATIENTS
CN115554370B (zh) 一种改善自身免疫性甲状腺炎的组合物及其应用
US10646553B2 (en) Use of recombinant human calcineurin B subunit
HK1025737B (en) Treatment of multiple sclerosis through ingestion of copolymer-1
Brod Gut response: therapy with ingested immunomodulatory proteins
RU2153872C2 (ru) Способ лечения дифтерии
SU1205915A1 (ru) Способ лечени аллергических заболеваний
US6068844A (en) Increased resistance to stroke by developing immunologic tolerance to myelin or components thereof
RU2008007C1 (ru) Способ лечения острого вирусного гепатита
MXPA99006457A (en) Treatment of multiple sclerosisthrough ingestion or inhalation of copolymer-1
CN108175821A (zh) 一种清益调免方及其应用
Aschenbrenner Vonoprazan approved for nonerosive esophagitis
CN106539816A (zh) 环二核苷酸在防治多发性硬化症中的应用
WO2022174378A1 (zh) 痘苗病毒致炎兔皮提取物治疗神经系统脱髓鞘疾病的用途
UA31530U (uk) Спосіб корекції метаболічних порушень у хворих з ранніми формами раку прямої кишки
UA69729A (en) Method for correcting peroxidation in patients with multiple peptic ulcers of stomach and duodenum upon surgical treatment

Legal Events

Date Code Title Description
MK4A Patent expired

Designated state(s): AM AZ BY KZ KG MD TJ TM RU